Experimental MS drug prevents relapses in nine out of 10 patients

A UC San Francisco-led study found that ofatumumab, a drug that targets immune B cells, reduced relapses by half in the first year. In the second, attacks stopped altogether most patients. https://www.dailymail.co.uk/health/article-8597577/Experimental-MS-drug-prevents-relapses-nine-10-patients.html?ns_mchannel=rss&ns_campaign=1490&ito=1490